Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial The results of the interim ...

Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer ...

Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial ASCO Rapid Recommendation ...

Fig 2. Updated Recommendations. C, conditional; ECOG, Eastern Cooperative Oncology Group; L, low; LS, limited-stage; M, moderate; PS, performance status; S, strong; SCLC, small cell lung cancer. Which ...

Managing PABC is challenging, as both maternal and fetal health must be prioritized without compromising cancer outcomes. Although treatment should be as close as possible to the standard treatment ...

Sixty-two patients were enrolled in the study, with 53.2% female patients and a median age of 68 years. The most prevalent malignancy was thoracic (62.9%). The feasibility metric was met, with 45 ...

In the article that accompanies this editorial, Wu et al 36 observed that residential exposure to fine particulate matter was associated with higher breast cancer incidence using prospective data from ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials? A thorough literature search was ...